Loring Wolcott & Coolidge Fiduciary Advisors’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.74M | Sell |
36,192
-69,362
| -66% | -$2.98M | 0.02% | 134 |
|
|
2026
Q1 | $3.96M | Sell |
105,554
-1,844
| -2% | -$87.4K | 0.04% | 93 |
|
|
2025
Q4 | $6.75M | Sell |
107,398
-4,623
| -4% | -$236K | 0.06% | 80 |
|
|
2025
Q3 | $5.96M | Sell |
112,021
-6,219
| -5% | -$364K | 0.05% | 80 |
|
|
2025
Q2 | $8.16M | Sell |
118,240
-2,790
| -2% | -$190K | 0.07% | 74 |
|
|
2025
Q1 | $7.42M | Buy |
121,030
+7,342
| +6% | +$606K | 0.07% | 75 |
|
|
2024
Q4 | $9.95M | Buy |
113,688
+81,557
| +254% | +$8.82M | 0.09% | 75 |
|
|
2024
Q3 | $3.66M | Sell |
32,131
-674
| -2% | -$89.9K | 0.03% | 109 |
|
|
2024
Q2 | $4.62M | Buy |
32,805
+12,504
| +62% | +$1.66M | 0.04% | 87 |
|
|
2024
Q1 | $2.54M | Sell |
20,301
-135
| -0.7% | -$16.1K | 0.03% | 104 |
|
|
2023
Q4 | $2.34M | Hold |
20,436
| – | – | 0.02% | 107 |
|
|
2023
Q3 | $2.06M | Sell |
20,436
-160
| -0.8% | -$14.1K | 0.02% | 111 |
|
|
2023
Q2 | $1.67M | Hold |
20,596
| – | – | 0.02% | 123 |
|
|
2023
Q1 | $1.64M | Sell |
20,596
-1,302
| -6% | -$92.3K | 0.02% | 120 |
|
|
2022
Q4 | $1.48M | Hold |
21,898
| – | – | 0.02% | 128 |
|
|
2022
Q3 | $1.09M | Hold |
21,898
| – | – | 0.01% | 141 |
|
|
2022
Q2 | $1.22M | Hold |
21,898
| – | – | 0.02% | 142 |
|
|
2022
Q1 | $1.22M | Hold |
21,898
| – | – | 0.01% | 145 |
|
|
2021
Q4 | $1.23M | Sell |
21,898
-320
| -1% | -$17.3K | 0.01% | 155 |
|
|
2021
Q3 | $1.07M | Sell |
22,218
-1,840
| -8% | -$89K | 0.01% | 160 |
|
|
2021
Q2 | $1.01M | Sell |
24,058
-238
| -1% | -$9.23K | 0.01% | 172 |
|
|
2021
Q1 | $819K | Sell |
24,296
-54
| -0.2% | -$1.92K | 0.01% | 170 |
|
|
2020
Q4 | $850K | Buy |
24,350
+550
| +2% | +$19K | 0.01% | 166 |
|
|
2020
Q3 | $826K | Hold |
23,800
| – | – | 0.01% | 156 |
|
|
2020
Q2 | $779K | Buy |
23,800
+1,000
| +4% | +$31.9K | 0.01% | 145 |
|
|
2020
Q1 | $686K | Sell |
22,800
-9,380
| -29% | -$279K | 0.01% | 151 |
|
|
2019
Q4 | $931K | Sell |
32,180
-26,320
| -45% | -$729K | 0.01% | 160 |
|
|
2019
Q3 | $1.51M | Sell |
58,500
-13,940
| -19% | -$352K | 0.02% | 130 |
|
|
2019
Q2 | $1.85M | Sell |
72,440
-60,884
| -46% | -$1.5M | 0.03% | 120 |
|
|
2019
Q1 | $3.49M | Sell |
133,324
-1,058,558
| -89% | -$26M | 0.05% | 100 |
|
|
2018
Q4 | $27.5M | Sell |
1,191,882
-145,622
| -11% | -$3.24M | 0.5% | 48 |
|
|
2018
Q3 | $31.5M | Sell |
1,337,504
-114,464
| -8% | -$2.79M | 0.5% | 49 |
|
|
2018
Q2 | $33.5M | Sell |
1,451,968
-193,242
| -12% | -$4.59M | 0.58% | 44 |
|
|
2018
Q1 | $40.5M | Sell |
1,645,210
-440,662
| -21% | -$11.6M | 0.74% | 38 |
|
|
2017
Q4 | $56M | Sell |
2,085,872
-71,448
| -3% | -$1.82M | 1.03% | 35 |
|
|
2017
Q3 | $51.9M | Sell |
2,157,320
-84,778
| -4% | -$1.92M | 1% | 35 |
|
|
2017
Q2 | $47.5M | Sell |
2,242,098
-375,316
| -14% | -$7.57M | 0.94% | 37 |
|
|
2017
Q1 | $44.9M | Sell |
2,617,414
-289,704
| -10% | -$5.04M | 0.94% | 35 |
|
|
2016
Q4 | $52.1M | Sell |
2,907,118
-575,840
| -17% | -$10.4M | 1.16% | 28 |
|
|
2016
Q3 | $72.4M | Buy |
3,482,958
+53,128
| +2% | +$1.32M | 1.66% | 24 |
|
|
2016
Q2 | $92.2M | Sell |
3,429,830
-28,364
| -0.8% | -$778K | 2.12% | 14 |
|
|
2016
Q1 | $93.7M | Sell |
3,458,194
-10,940
| -0.3% | -$293K | 2.21% | 13 |
|
|
2015
Q4 | $101M | Buy |
3,469,134
+63,080
| +2% | +$1.75M | 2.49% | 12 |
|
|
2015
Q3 | $93.3M | Hold |
3,406,054
| – | – | 2.38% | 11 |
|
|
2015
Q2 | $93.3M | Sell |
3,406,054
-101,226
| -3% | -$2.85M | 2.38% | 11 |
|
|
2015
Q1 | $93.6M | Sell |
3,507,280
-17,224
| -0.5% | -$397K | 2.36% | 12 |
|
|
2014
Q4 | $74.6M | Sell |
3,524,504
-68,148
| -2% | -$1.52M | 1.91% | 18 |
|
|
2014
Q3 | $85.5M | Sell |
3,592,652
-18,798
| -0.5% | -$433K | 2.31% | 14 |
|
|
2014
Q2 | $83.4M | Sell |
3,611,450
-25,386
| -0.7% | -$560K | 2.26% | 17 |
|
|
2014
Q1 | $83M | Buy |
3,636,836
+8,116
| +0.2% | +$173K | 2.27% | 16 |
|
|
2013
Q4 | $67M | Buy |
3,628,720
+96,200
| +3% | +$1.68M | 1.85% | 19 |
|
|
2013
Q3 | $59.8M | Buy |
3,532,520
+106,200
| +3% | +$1.79M | 1.82% | 19 |
|
|
2013
Q2 | $53.1M | Buy |
+3,426,320
| New | +$57M | 1.66% | 22 |
|
Other funds holding NVO
EHC
SRIM
MG
OAM
Loring Wolcott & Coolidge Fiduciary Advisors's NVO Position: Q2 2026 in Review
Loring Wolcott & Coolidge Fiduciary Advisors reduced its Novo Nordisk (NVO) stake by 66% in Q2 2026, selling an estimated $2.98M and leaving 36,192 shares worth $1.74M. The position accounts for 0.02% of the portfolio, ranked #134.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in NVO in Q2 2013 and has held it in 53 quarters since. The position peaked at $101M in Q4 2015. 819 funds tracked by Wall St. Rank hold NVO as of Q2 2026.
- Loring Wolcott & Coolidge Fiduciary Advisors held 36,192 shares of Novo Nordisk worth $1.74M as of Q2 2026.
- Loring Wolcott & Coolidge Fiduciary Advisors sold 69,362 Novo Nordisk shares in Q2 2026, an estimated $2.98M.
- Novo Nordisk made up 0.02% of Loring Wolcott & Coolidge Fiduciary Advisors's portfolio in Q2 2026, its #134 holding.
- Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Novo Nordisk in Q2 2013 and has held it in 53 quarters since.
- Loring Wolcott & Coolidge Fiduciary Advisors's Novo Nordisk position peaked at $101M in Q4 2015.
- 819 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.
Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.